Stopping MYC in Cancer with New Medications
Targeting MYC promoter G-quadruplex for MYC inhibition by Indenoisoquinolines
This work explores new ways to stop the MYC gene, which is often overactive in many cancers, using a special type of drug.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purdue University NIH-funded |
| Lab location | 1 site (West Lafayette, United States) |
| Project ID | NIH-11112395 on NIH RePORTER |
What this research studies
Our bodies have a special DNA structure called a G-quadruplex (G4) that can act like a switch to turn genes on or off. In many cancers, a gene called MYC is overactive, helping cancer cells grow. This project focuses on a specific G4 structure within the MYC gene that can silence it. We are developing new drugs, called indenoisoquinolines, that can bind to this G4 structure and turn down MYC activity. We are also learning how a protein called DDX5 interacts with this G4 to better understand how to control MYC.
Who could benefit from this research
Good fit: This foundational research is for patients with cancers where the MYC gene is overactive, as future treatments could be developed for them.
Not a fit: Patients whose cancers do not involve MYC gene overactivity or those seeking immediate clinical treatments would not directly benefit from this early-stage research.
Why it matters
Potential benefit: If successful, this work could lead to new and more effective anti-cancer drugs that specifically target the MYC gene, potentially improving treatment options for many types of cancer.
How similar studies have performed: Other studies have shown that targeting G-quadruplexes in the MYC promoter can lower MYC levels in cancer cells, and the indenoisoquinoline scaffold has been tested clinically.
Where this research is happening
West Lafayette, United States
- Purdue University — West Lafayette, United States (Active)
Researchers
- Principal investigator: Yang, Danzhou — Purdue University
- Study coordinator: Yang, Danzhou
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.